In rings of rat aorta, cyclopiazonic acid (CPA), a selective inhibitor of the internal membrane Ca2+-pump ATPase, gradually initiated a concentration-dependent contraction which was much less in endothelium-intact than in endothelium-denuded rings. In phenylephrine-precontracted rings with intact endothelium, CPA, like acetylcholine, produced endothelium-dependent relaxations in a concentration-dependent manner. These were nearly abolished by methylene blue (MB) or NG-nitro-L-arginine methylester (L·NAME). This inhibitory effect of L·NAME was reversed by L·arginine but not by D-arginine, indicating that CPA induced a release of endothelium-derived relaxing factor (EDRF) from endothelial cells leading to smooth muscle relaxation. Concentration-dependent relaxations induced by sodium nitroprusside, which is thought to act by releasing nitric oxide, were not inhibited by L·NAME, but were inhibited similarly by MB in endothelium-intact and -denuded rings. These results indicate that CPA causes EDRF-release from endothelial cells and support the recent hypothesis that release of intracellular Ca from stores is the initiating factor in EDRF release, possibly allowing ongoing Ca entry to sustain release.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.